[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367995-105":59,"doc-detail-367995-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","machine-learning-for-identifying-liver-and-pancreas-cancers-through-comprehensive-serum-glycopeptide-spectra-analysis-a-case-control-study","Machine learning for identifying liver and pancreas cancers through comprehensive serum glycopeptide spectra analysis - a case-control study","","Liver and pancreatic cancers are difficult to detect early, resulting in high mortality. This case-control study evaluates comprehensive serum glycopeptide spectra analysis (CSGSA) by combining enriched glycopeptides derived from liquid chromatography-mass spectrometry with conventional blood tumor markers via machine learning. Nine markers (including CA19-9 and AFP) were assessed in 119 pancreatic cancer patients and 49 hepatocellular carcinoma patients, plus 590 healthy controls. Two fully sialylated biantennary glycan-associated proteins and the integrated model achieved strong discrimination with an ROC AUC of 0.996, supporting minimally invasive screening potential.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/machine-learning-for-identifying-liver-and-pancreas-cancers-through-comprehensive-serum-glycopeptide-spectra-analysis-a-case-control-study/367995/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/machine-learning-for-identifying-liver-and-pancreas-cancers-through-comprehensive-serum-glycopeptide-spectra-analysis-a-case-control-study/367995.png","ImageObject",300,407,{"name":92,"@type":93},"nayy☆","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is CSGSA in this study?","Question",{"text":113,"@type":114},"CSGSA is a diagnostic approach that combines enriched serum glycopeptides with conventional tumor markers using machine learning. The glycopeptides are analyzed by liquid chromatography-mass spectrometry.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which patient groups and controls were analyzed?",{"text":118,"@type":114},"The study included 119 patients with pancreatic cancer, 49 with hepatocellular carcinoma, and 590 healthy controls for comparative analysis of biomarkers and glycopeptide spectra.",{"name":120,"@type":111,"acceptedAnswer":121},"How accurate was the integrated diagnostic model?",{"text":122,"@type":114},"Integrating two key glycopeptides with nine tumor markers and 1688 enriched glycopeptides produced a receiver operating characteristic area under the curve (ROC AUC) score of 0.996.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},367995,1790439136,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Machine learning for identifying liver and pancreas cancers through comprehensive serum glycopeptide spectra analysis: a case-control study  \nMotoyuki Kohjima 1, Yuko Takami2, Ken Kawabe 1, Kazuhiro Tanabe3 , Chihiro Hayashi3, Mikio Mikami4 and Tetsuya Kusumoto5  \n1 Department of Gastroenterology, NHO Kyushu Medical Center, Fukuoka, Japan  \n2 Department of Hepato-Biliary-Pancreatic Surgery, NHO Kyushu Medical Center, Fukuoka, Japan  \n3 Medical Solution Promotion Department, Medical Solution Segment, LSI Medience Corporation, Tokyo, Japan  \n4 Chigasaki Central Hospital, Women’s Center, Kanagawa, Japan  \n5 Department of Gastrointestinal Surgery and Clinical Research Institute Cancer, Research Division, NHO Kyushu Medical Center, Fukuoka, Japan  \nKeywords  \nblood-based diagnostics; glycopeptides; liver cancer; machine learning; pancreatic cancer; tumor markers  \nCorrespondence  \nK. Tanabe, 3-30-1, Shimura, Itabashi, Tokyo, 174-8555, Japan  \nTel: +81-70-5597-7284  \nE-mail: [kazuhirotanabe77@gmail.com](kazuhirotanabe77@gmail.com)  \n(Received 13 February 2025, revised 27 May 2025, accepted 1 June 2025, available online 1 July 2025)  \ndoi:10 . 1002/1878-0261 .70084  \nLiver and pancreatic cancers are difﬁcult to detect early, leading to high mortality rates. Blood-based diagnostics present a viable alternative for earlier detection, potentially improving survival rates. The comprehensive serum glycopeptide spectra analysis (CSGSA) method combines enriched glycopeptides (EGPs) with conventional tumor markers through machine learning to accurately identify early stage cancers. Here, we analyzed nine tumor markers (CA19-9, AFP, PSA, CEA, CA125, CYFRA, CA15-3, SCC antigen, and NCC-ST439) in 119 patients with pancreatic cancer and 49 with hepatocellular carcinoma, alongside 590 healthy controls. We also analyzed EGPs using liquid chromatography-mass spectrometry. We found that α 1-antitrypsin with a fully sialylated biantennary glycan at asparagine 271 and α2-macroglobulin with a fully sialylated biantennary glycan atasparagine 70 effectively distinguished liver and pancreatic cancers. The integration of these two glycopeptides, along with the nine tumor markers and 1688 EGPs using a machine learning model enhanced diagnostic accuracy, achieving a receiver operating characteristic-area under curve (ROCAUC) score of 0 .996. CSGSA has the potential to minimize the need for invasive diagnostic procedures and serves as a promising tool for widespread screening.  \n1. Introduction  \nHepatocellular carcinoma (HCC) and pancreatic cancer (PAC) are responsible for hundreds of thousands of new diagnoses worldwide each year, affecting various racial groups [1] . Despite progress in medical technology, these cancers often result in high mortality  \nrates when detected at advanced stages, primarily due to vague early symptoms and the limitations of conventional diagnostic techniques. In Japan, there are about 37 000 new cases of HCC annually, leading to approximately 25 000 deaths [2] . Similarly, PAC has  \nAbbreviations  \nAFP, alpha-fetoprotein; CA125, cancer antigen 125; CEA, carcinoembryonic antigen; CSGSA, comprehensive serum glycopeptide spectra analysis; HCC, hepatocellular carcinoma; LC–MS, liquid chromatography-mass spectrometer; PAC, pancreatic cancer; PPV, positive predictive value; PSA, prostate-speciﬁc antigen; QC, quality control.  \nMolecular Oncology 19 (2025) 3499–3517 ª 2025 The Author(s) . Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n3499  \nSerum glycopeptides in cancer detection via ML M. Kohjima et al.  \nan annual incidence of around 44 000 cases, resulting in an estimated 38 000 deaths [2] . The 5-year survival rate for HCC and PAC drops to 2–3% when diagnosed at l","cbCaitRaWMZGyy6I","https://ap.wps.com/l/cbCaitRaWMZGyy6I","pdf",2629317,"English","# Introduction\n## Abbreviations","[{\"question\":\"What is CSGSA in this study?\",\"answer\":\"CSGSA is a diagnostic approach that combines enriched serum glycopeptides with conventional tumor markers using machine learning. The glycopeptides are analyzed by liquid chromatography-mass spectrometry.\"},{\"question\":\"Which patient groups and controls were analyzed?\",\"answer\":\"The study included 119 patients with pancreatic cancer, 49 with hepatocellular carcinoma, and 590 healthy controls for comparative analysis of biomarkers and glycopeptide spectra.\"},{\"question\":\"How accurate was the integrated diagnostic model?\",\"answer\":\"Integrating two key glycopeptides with nine tumor markers and 1688 enriched glycopeptides produced a receiver operating characteristic area under the curve (ROC AUC) score of 0.996.\"}]","Machine learning for identifying liver and pancreas cancers through comprehensive serum glycopeptide spectra analysis - a case-control study | PDF",1790174259,48,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/765e63cc6221825b2be23b46512e6fe7.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/023ef9ce83c16cf2e46b6eb040c2b857.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e3a18833ace6d77b31fd444ea51c71e.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a61d0d0c22b6351f0a0704cfb41041fa.webp",980,1287]